The Iovance Gen 2 manufacturing process improved over classical TIL expansion methods by dependably delivering potent cryopreserved drug products with greatly reduced manufacturing cycle time. Drug products generated by this process displayed favorable quality attributes for adoptive transfer across the 5 solid tumor indications.

**Drug products generated across multiple solid tumor indications with Gen 2 processes across all primary indications exhibit a robust functional T-cell population.**

The mean viable cell dose and viability of drug products across the 5 solid tumor indications produced by 5x10^5 viable γδ T-cells were comparable to lifileucel with broadly overlapping 95% CI.

**DISCLOSURE**

© Iovance Biotherapeutics, Inc. 2019